$MNKD

Avaí Bio begins manufacturing genetically modified cells overexpressing α-Klotho protein, an anti-aging compound that naturally declines 50% after age 40, advancing its Cell-in-a-Box platform.

MannKind beat revenue expectations with 46% growth, but stock fell 7% due to disappointing earnings and elevated operational costs from acquisition integration.

MannKind's CEO will present at Oppenheimer Conference on February 26 while the company enrolls first patient in pediatric diabetes trial for its Afrezza insulin therapy.